United States Drug Manufacturers - General news

14:11 29 Jul 2026

BioSpace Regulatory and legal Main company 🇺🇸 United States

Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court

A U.S. District Judge in New Jersey has ruled that Novo Nordisk must face fraud allegations from shareholders regarding its weight loss drug CagriSema. Shareholders claim Novo withheld crucial information about protocol changes in a Phase 3 study, leading them to purchase shares at …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

14:00 29 Jul 2026

Financial Times Market update Main company 🇺🇸 United States

Pfizer's PREVNAR 20™ Selected for Québec's Publicly Funded Pediatric Pneumococcal Immunization Program

Pfizer's PREVNAR 20™, a 20-valent pneumococcal conjugate vaccine, has been chosen for Québec's publicly funded pediatric immunization program, making it the second Canadian province to adopt it. This initiative aims to provide broader serotype coverage against severe pneumococcal disease in infants and children. Healthcare …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

13:56 29 Jul 2026

MarketBeat Analyst action Main company 🇺🇸 United States

Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $150.00

Barclays has raised its price target for Merck & Co., Inc. (NYSE:MRK) to $150.00 from $140.00, maintaining an "overweight" rating and suggesting a 13.77% upside. This adjustment aligns with an overall positive analyst sentiment, as 13 Buy ratings and seven Hold ratings contribute to …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

13:38 29 Jul 2026

Market source Earnings Main company 🇺🇸 United States

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

This article analyzes Merck & Co., Inc. (MRK) beyond its trending stock status, focusing on factors like earnings estimate revisions, revenue growth, and valuation. Zacks Investment Research downgraded Merck to a Zacks Rank #4 (Sell) due to recent changes in consensus estimates, suggesting potential …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

13:37 29 Jul 2026

Seeking Alpha Earnings Main company 🇺🇸 United States

Biogen Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BIIB) 2026-07-29

This article presents the Biogen Inc. Q2 2026 earnings call presentation. Key financial highlights include an EPS of $3.60, beating estimates by $1.57, and revenue of $2.74 billion, a 3.42% year-over-year increase, surpassing estimates by $275.37 million. The slide deck was published in conjunction …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

13:23 29 Jul 2026

Simply Wall St Earnings Main company 🇺🇸 United States

Amgen (AMGN) Stock Could Be A Bargain On Cash Flow But Fairly Priced On Earnings

Amgen stock has shown an 88.5% total return over the past five years. A Discounted Cash Flow (DCF) analysis suggests it is undervalued by 43.0% on cash flow, implying a potential bargain. However, its current P/E ratio of 27.2x, which is above the biotech …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

13:10 29 Jul 2026

WTVB Deals and strategy Main company 🇺🇸 United States

Biogen beats quarterly estimates as newer drugs drive growth

Biogen exceeded Wall Street's expectations for its second-quarter profit and revenue, driven by strong growth in its rare-disease medications despite a decline in sales of its older multiple sclerosis drugs. The company raised its full-year revenue forecast to a mid-single-digit percentage growth, a significant …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

13:08 29 Jul 2026

The Globe and Mail Earnings Main company 🇺🇸 United States

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

This article compares the revenue growth strategies of Johnson & Johnson (JNJ) and Eli Lilly (LLY). While J&J offers reliable stability with slower, steady growth, Eli Lilly shows rapid revenue expansion, primarily driven by its diabetes and obesity drugs. Investors are advised to watch …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

12:41 29 Jul 2026

Investing.com Earnings Main company 🇺🇸 United States

Amarin reports 42% revenue drop on prior year licensing payment

Amarin Corporation reported a 42% year-over-year decrease in second-quarter net revenue, primarily due to the absence of a $25 million licensing payment received from Recordati in the prior year. Despite the revenue drop, the company's operating expenses fell by 59% due to cost-saving initiatives, …

AMRN main company

Sharemaestro market context Price below Trend Line 52 weeks -12.0%

12:41 29 Jul 2026

StreetInsider Earnings Main company 🇺🇸 United States

Amarin Corp. (AMRN) Reports In-Line Q2 EPS

Amarin Corp. (AMRN) announced its second-quarter earnings, reporting an in-line EPS of $0.00. The company's revenue for the quarter reached $42.2 million. This financial update provides key figures for investors interested in Amarin's recent performance.

AMRN main company

Sharemaestro market context Price below Trend Line 52 weeks -12.0%

12:41 29 Jul 2026

10TV Earnings Main company 🇺🇸 United States

Amarin: Q2 Earnings Snapshot

This article provides an earnings snapshot for Amarin's Q2 performance. It is a very brief announcement, indicating that the company's Q2 earnings were in line with expectations.

AMRN main company

Sharemaestro market context Price below Trend Line 52 weeks -12.0%

12:37 29 Jul 2026

The Motley Fool Market update Main company 🇺🇸 United States

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Amgen is developing MariTide, a monthly injectable weight loss drug, aiming to compete with Eli Lilly's and Novo Nordisk's established treatments. While MariTide offers convenience with its once-a-month dosing, its phase 2 trial data showed less efficacy compared to rival drugs like Eli Lilly's …

LLY main company AMGN main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

12:30 29 Jul 2026

KBR Market update Main company 🇺🇸 United States

Sanofi Korea, postpartum care group renew MOU to strengthen infection prevention

Sanofi Korea and the Korea Postpartum Association have renewed their Memorandum of Understanding (MOU) to enhance cooperation in infection prevention and management for mothers and newborns. This extension builds upon their initial 2023 agreement, under which they've conducted educational programs and awareness campaigns, including …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

12:13 29 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

The Manufacturers Life Insurance Company Raises Stock Holdings in Bristol Myers Squibb Company $BMY

The Manufacturers Life Insurance Company increased its holdings in Bristol Myers Squibb (NYSE:BMY) by 15.8% in the first quarter, adding 241,405 shares to reach a total value of approximately $107.1 million. Institutional investors now own 76.41% of BMY, while analyst sentiment remains mixed with …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

12:13 29 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Opal Capital LLC Buys Shares of 22,664 Bristol Myers Squibb Company $BMY

Opal Capital LLC recently acquired 22,664 shares of Bristol Myers Squibb (NYSE:BMY) in the first quarter, valued at approximately $1,375,000. Other institutional investors have also adjusted their holdings in the biopharmaceutical company, which has seen its stock perform within a 12-month range of $42.52 …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

12:10 29 Jul 2026

Moomoo Market update Main company 🇺🇸 United States

Why GSK Plc (GSK) Stock Is Up Today

This article explains why GSK Plc's stock is experiencing an increase today. It details the specific factors and news items contributing to the positive movement in GSK's share price.

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

12:07 29 Jul 2026

Market source Earnings Main company 🇺🇸 United States

Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates

Biogen Inc. (BIIB) reported Q2 earnings of $3.6 per share, surpassing the Zacks Consensus Estimate of $3.04, and revenues of $2.74 billion, exceeding estimates by 9.40%. The company has consistently beaten EPS and revenue estimates over the past four quarters. Despite the positive results, …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

12:06 29 Jul 2026

Seeking Alpha Deals and strategy Main company 🇺🇸 United States

Biogen posts Q2 beat and updates 2026 outlook (BIIB:NASDAQ)

Biogen (BIIB) reported better-than-expected Q2 2026 results, driven by strong performance in its growth portfolio, which includes newer medicines like Zurzuvae and Skyclarys. The company raised its full-year revenue outlook to mid-single-digit percentage growth, despite a minor underperformance from Leqembi and a reduced EPS …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

12:02 29 Jul 2026

GuruFocus Earnings Main company 🇺🇸 United States

Is Biogen Inc (BIIB) Overvalued After Q2 Earnings With EPS of $0.66 and Revenue of $2,736 Million? GF Score: 69/100

Biogen Inc (BIIB) reported Q2 2026 revenue of $2.736 billion, a 3% increase year-over-year, and a GAAP diluted EPS of $0.66. While its Growth Portfolio revenue surpassed its legacy MS portfolio, declining revenue from foundational MS products remains a challenge. GuruFocus rates BIIB with …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

11:30 29 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Talon Private Wealth LLC Acquires Shares of 3,086 Amgen Inc. $AMGN

Talon Private Wealth LLC recently acquired 3,086 shares of Amgen Inc. (NASDAQ:AMGN) in the first quarter, valued at approximately $1,086,000. Other institutional investors have also adjusted their holdings, with Amgen's stock seeing a 4.5% increase and analysts providing mixed ratings, though the consensus remains …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

11:23 29 Jul 2026

WSJ Deals and strategy Main company 🇺🇸 United States

Biogen Cuts FY Adjusted View as Profit Declines

Biogen (BIIB) reported a significant decline in its second-quarter profit and subsequently lowered its full-year adjusted earnings forecast. The biopharmaceutical company attributed the reduced profit and revised outlook to deal-related charges, research and development expenses, the acquisition of Apellis, and ongoing investments in Phase …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

11:13 29 Jul 2026

TradingView Deals and strategy Main company 🇺🇸 United States

Biogen reports Q2 2026: $2.74B revenue, GAAP EPS $0.66, Non‑GAAP EPS $3.60

Biogen reported its second-quarter 2026 results, showing total revenue of $2.74 billion, a 3% increase year-over-year. The company posted GAAP diluted EPS of $0.66 and non-GAAP diluted EPS of $3.60, with its Growth Portfolio contributing $1.06 billion, up 24% year-over-year. Biogen also updated its …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

11:11 29 Jul 2026

Stock Titan Earnings Main company 🇺🇸 United States

Grifols (NASDAQ: GRFS) boosts H1 profit 28.7% and refinances 2027 debt

Grifols reported a 28.7% increase in H1 2026 profit to €227 million, with revenue reaching €3.57 billion. The company successfully refinanced all 2027 debt maturities, extending its maturity profile to Q4 2028 and strengthening its financial flexibility. This performance, driven by its Biopharma segment …

GRFS main company

Sharemaestro market context Price below Trend Line 52 weeks -23.4%

11:02 29 Jul 2026

Breakingthenews.net Earnings Main company 🇺🇸 United States

Biogen Q2 revenue rises 3% to $2.7B

Biogen announced a 3% increase in its second-quarter revenue, reaching $2.7 billion. This growth indicates a positive financial performance for the company during the quarter.

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

11:02 29 Jul 2026

Barron's Earnings Main company 🇺🇸 United States

Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs

Biogen has increased its full-year revenue guidance, now expecting a mid-single-digit percentage increase, a significant turnaround from its previous outlook of a similar decline. This positive revision comes as the company's new growth portfolio of drugs successfully offsets falling revenues from its established multiple …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

10:52 29 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Merck & Co., Inc. $MRK Shares Sold by Redwood Grove Capital LLC

Redwood Grove Capital LLC significantly reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 78.5% in the first quarter, selling 109,600 shares and now holding 30,068 shares valued at $3,617,000. Despite this, other hedge funds and institutional investors have either increased their positions …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

10:37 29 Jul 2026

TradingKey Analyst action Main company 🇺🇸 United States

BMY|Bristol-Myers Squibb Co|Price:63.635|Chg%:+1.075

This article provides a comprehensive overview of Bristol-Myers Squibb Co (BMY) stock, including real-time quotes, key financial figures, performance trends, and analyst ratings. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the pharmaceuticals industry. The stock is currently rated …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

10:37 29 Jul 2026

Revelio Labs Earnings Main company 🇺🇸 United States

Biogen Number of Employees 2026 | Employee Count & Headcount Data

Biogen, Inc. (BIIB) reported approximately 7,578 total employees worldwide as of March 2026, marking a 13.6% decline from 2023. Despite this, the company is actively hiring, with 572 active job postings in 2026, a 37.6% increase from the previous year. The workforce is concentrated …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

10:23 29 Jul 2026

Market source Earnings Main company 🇺🇸 United States

AbbVie (ABBV) Stock May Be Mispriced On Its 172% Run

AbbVie (ABBV) has seen strong returns over five years (172%), but its current valuation presents a mixed picture. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 43.4% at an intrinsic value of $465 per share, its Price-to-Earnings (P/E) ratio …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

10:11 29 Jul 2026

pharmaphorum Regulatory and legal Main company 🇺🇸 United States

US judge says Novo Nordisk must face lawsuit over CagriSema

A US judge has ruled that Novo Nordisk must face certain allegations in court regarding a class-action lawsuit. The lawsuit claims the company defrauded investors with misleading comments about the REDEFINE-1 trial for its obesity drug, CagriSema, particularly concerning dosing information and "overwhelmingly positive …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

10:11 29 Jul 2026

TradingKey Market update Main company 🇺🇸 United States

Mira Pharmaceuticals Inc (MIRA) Institutional Confidence

This article provides an analysis of Mira Pharmaceuticals Inc (MIRA) institutional confidence score, which currently stands at 3.00 with no change since the previous score. It details the shares held by various institutional investors, including Bay Shore Trust, McNulty (Brian Patrick), and Geode Capital …

MIRA main company

Sharemaestro market context Price below Trend Line 52 weeks -45.4%

09:38 29 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

California State Teachers Retirement System Sells 110,513 Shares of Merck & Co., Inc. $MRK

The California State Teachers Retirement System reduced its holdings in Merck & Co., Inc. by 2.8% in the first quarter, selling 110,513 shares and retaining 3,835,612 shares valued at $461.39 million. This sale comes amidst mixed analyst sentiment for Merck, with some positive news …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

09:28 29 Jul 2026

Moomoo Market update Main company 🇺🇸 United States

Merck & Co. on Track for Record High Close -- Data Talk

The article indicates that Merck & Co. is poised to close at a new record high. This positive performance is highlighted in a "Data Talk" piece, suggesting a focus on financial and company data.

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

09:20 29 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Empire Financial Management Company LLC Sells 7,623 Shares of Merck & Co., Inc. $MRK

Empire Financial Management Company LLC reduced its stake in Merck & Co., Inc. by 16% in the first quarter, selling 7,623 shares and retaining 39,960 shares valued at approximately $4.8 million. Other institutional investors have increased their holdings, with overall institutional ownership at 76.07%. …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

09:20 29 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

California State Teachers Retirement System Has $201.19 Million Stake in Bristol Myers Squibb Company $BMY

The California State Teachers Retirement System reduced its stake in Bristol Myers Squibb Company (BMY) by 2.3% in the first quarter, now owning 3,317,201 shares valued at $201.19 million. Other institutional investors have also adjusted their positions in the biopharmaceutical company. Analysts currently rate …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

09:18 29 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Gateway Wealth Partners LLC Has $2 Million Position in Merck & Co., Inc. $MRK

Gateway Wealth Partners LLC significantly increased its stake in Merck & Co., Inc. (NYSE:MRK) by 271.9% in the first quarter, now holding 16,631 shares valued at over $2 million. This move is part of a broader trend of institutional investors adjusting their positions in …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%